


Lewy-Dx: The First Blood Test to Diagnose Dementia with Lewy Bodies

OVERVIEW



A new dementia case occurs every three seconds, with many cases being misdiagnosed as Alzheimer's (AD) instead of dementia with Lewy bodies (DLB). This causes professionals to give patients the wrong treatment, leading to severe side effects or even death. To address this, the Lewy-Dx test uses a simple blood sample to measure specific miRNAs and accurately distinguish DLB from AD, improving diagnosis and treatment.



PROJECT

Sector: Neuroscience, Dementia

R&D direction:

IVD kit to differentiate between AD and Lewy's bodies and analyse the prognosis of the patient

Stage of development: TRL4-5

Scientific leader: Dr. Katrin Beyer



PRODUCT

Potential indications:

Dementia & Alzheimer's disease

Mechanism of action:

Detection and quantification of specific miRNA in blood platelets

Market Size: €8B in 2023



IP PROTECTION

Patent Filed



NEED

Dementia with Lewy bodies (DLB) is the second leading cause of dementia after Alzheimer's disease (AD) but, due to its clinical similarities with AD, only **30% of cases** are correctly diagnosed, leading to inappropriate treatments with severe side effects and hindering AD drug trials. Lewy-Dx aims to address these challenges by **improving DLB diagnosis** and reducing misdiagnosis.



SOLUTION

The solution is based on the quantification of a specific set of molecules, known as miRNAs, which are present at varying levels in the blood platelets of DLB patients. Using a simple blood sample and standard laboratory techniques, combined with dedicated software, our diagnostic test can accurately differentiate DLB from AD, significantly improving diagnosis and enhancing patient management.



KEY ADVANTAGES

- ✓ Accurate diagnosis: distinguishes between DLB and AD, reducing misdiagnosis by up to 70%.
- ✓ Improved treatment: enables appropriate therapies for DLB patients, avoiding harmful side effects.
- ✓ Early detection: allows for timely diagnosis, improving patient management and outcomes.



OPPORTUNITY

License out

Spin-off generation

Co-development

CONTACT US!

innovation@igtp.cat

Innovation & Business Development Unit

